p57Kip2 (cdkn1c): Sequence, splice variants and unique temporal and spatial expression pattern in the rat pancreas

Laboratory Investigation

Volumn 85, Issue 3, 2005, Pages 364-375

  Potikha, Tamara ^a   Kassem, Sameer ^a   Haber, Esther P ^a   Ariel, Ilana ^a   Glaser, Benjamin ^a,b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

cell; cell proliferation; Alternative splice; CDKN1C; Cell cycle; Diabetes; Islet transplantation; p57Kip2; Pancreas regeneration

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P57; CDKN1C PROTEIN, HUMAN; CDKN1C PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; NUCLEAR PROTEIN;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SPECIFICITY; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; EMBRYO; ENZYME INHIBITION; EXOCRINE CELL; FETUS DEVELOPMENT; GENE EXPRESSION; GENE LOSS; GENOME IMPRINTING; HUMAN; HUMAN CELL; HYPERINSULINISM; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS; PANCREAS ISLET BETA CELL; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; RAT; SEQUENCE HOMOLOGY; ALTERNATIVE RNA SPLICING; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PRENATAL DEVELOPMENT; SPECIES DIFFERENCE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CLONING, MOLECULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P57; FETAL DEVELOPMENT; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; ORGAN SPECIFICITY; PANCREAS; RATS; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY;

EID: 14744305439     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700229     Document Type: Article

References (48)

1. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-649.
2. Matsuoka S, Edwards MC, Bai C, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-662.
3. Hatada I, Mukai T. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 1995;11:204-206.
4. Matsuoka S, Thompson JS, Edwards MC, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA 1996;93:3026-3030.
5. Taniguchi T, Okamoto K, Reeve AE. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour. Oncogene 1997;14:1201-1206.
6. Engel JR, Smallwood A, Harper A, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2000;37:921-926.
7. Hatada I, Mukai T. Genomic imprinting and Beckwith-Wiedemann syndrome. Histol Histopathol 2000;15: 309-312.
8. Maher ER, Reik W. Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest 2000;105: 247-252.
9. Algar EM, Deeble GJ, Smith PJ. CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance. J Med Genet 1999;36:524-531.
10. Lee MP, DeBaun M, Randhawa G, et al. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997;61:304-309.
11. O'Keefe D, Dao D, Zhao L, et al. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet 1997;61:295-303.
12. Bhuiyan ZA, Yatsuki H, Sasaguri T, et al. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome. Hum Genet 1999;104:205-210.
13. Hatada I, Inazawa J, Abe T, et al. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 1996;5:783-788.
14. Bourcigaux N, Gaston V, Logie A, et al. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab 2000;85:322-330.
15. Oya M, Schulz WA. Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 2000;83:626-631.
16. Tsugu A, Sakai K, Dirks PB, et al. Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol 2000;157:919-932.
17. Yan Y, Krisen J, Lee MH, et al. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997;11:973-983.
18. Zhang P, Liegeois NJ, Wong C, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
19. Takahashi K, Nakayama K. Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem (Tokyo) 2000;127: 73-83.
20. Glaser B. Hyperinsulinism of the newborn. Semin Perinatol 2000;24:150-163.
21. Dunne MJ, Cosgrove KE, Shepherd RM, et al. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev 2004;84:239-275.
22. Verkarre V, Fournet JC, de Lonlay P, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 1998;102:1286-1291.
23. Glaser B, Ryan F, Donath M, et al. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. Diabetes 1999;48:1652-1657.
24. Ryan FD, Devaney D, Joyce C, et al. Hyperinsulinism: the molecular aetiology of focal disease. Arch Dis Child 1998;79:445-447.
25. Kassem SA, Ariel I, Thornton PS, et al. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes 2000;49:1325-1333.
26. Kassem SA, Ariel I, Thornton PS, et al. p57(KIP2) expression in normal islet cells and in hyperinsulinism of infancy. Diabetes 2001;50:2763-2769.
27. Cattoretti G, Decker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
28. Kozak M. Adherence to the first-AUG rule when a second AUG codon follows closely upon the first. Proc Natl Acad Sci USA 1995;92:2662-2666.
29. Tokino T, Urano T, Furuhata T, et al. Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 1996;97:625-631.
30. Reynaud EG, Leibovitch MP, Tintignac LA, et al. Stabilization of MyoD by direct binding to p57(Kip2). J Biol Chem 2000;275:18767-18776.
31. Blakely EA, Bjornstad KA, Chang PY, et al. Growth and differentiation of human lens epithelial cells in vitro on matrix. Invest Ophthalmol Vis Sci 2000;41: 3898-3907.
32. Deschenes C, Vezina A, Beaulieu JF, et al. Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology 2001;120:423-438.
33. Mah N, Stoehr H, Schulz HL, et al. Identification of a novel retina-specific gene located in a subtelomeric region with polymorphic distribution among multiple human chromosomes. Biochim Biophys Acta 2001; 1522:167-174.
34. Overall M, Bakker M, Spencer J, et al. Genomic imprinting in the rat: linkage of Igf2 and H19 genes and opposite parental allele-specific expression during embryogenesis. Genomics 1997;45:416-420.
35. Morisaki H, Hatada I, Morisaki T, et al. A novel gene, ITM, located between p57KIP2 and IPL, is imprinted in mice. DNA Res 1998;5:235-240.
36. Awad MM, Sanders JA, Gruppuso PA. A potential role for p15(Ink4b) and p57(Kip2) in liver development. FEBS Lett 2000;483:160-164.
37. Nagahama H, Hatakeyama S, Nakayama K, et al. Spatial and temporal expression patterns of the cyclin-dependent kinase (CDK) inhibitors p27Kip1 and p57Kip2 during mouse development. Anat Embryol (Berl) 2001;203:77-87.
38. Burton PB, Yacoub MH, Barton PJ. Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development. Eur Heart J 1999;20:604-611.
39. Kochilas LK, Li J, Jin F, et al. p57Kip2 expression is enhanced during mid-cardiac murine development and is restricted to trabecular myocardium. Pediatr Res 1999;45:635-642.
40. Westbury J, Watkins M, Ferguson-Smith AC, et al. Dynamic temporal and spatial regulation of the cdk inhibitor p57(kip2) during embryo morphogenesis. Mech Dev 2001;109:83-89.
41. Yokoo T, Toyoshima H, Miura M, et al. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J Biol Chem 2003;278: 52919-52923.
42. Hiromura K, Haseley LA, Zhang P, et al. Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 2001;60:2235-2246.
43. Shankland SJ, Eitner F, Hudkins KL, et al. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 2000;58:674-683.
44. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001;58:1907-1922.
45. Zhang P, Wong C, DePinho RA, et al. Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev 1998;12:3162-3167.
46. Ikoma T, Ito T, Okudela K, et al. Modulation of the expression of the Cip/Kip family of cyclin-dependent kinase inhibitors in foetal developing lungs of hamsters. Cell Prolif 2001;34:233-241.
47. Stefan Y, Bordi C, Grasso S, et al. Beckwith-Wiedemann syndrome: a quantitative, immunohistochemical study of pancreatic islet cell populations. Diabetologia 1985;28:914-919.
48. Park CW, Chung JH. Age-dependent changes of p57(Kip2) and p21(Cip1/Waf1) expression in skeletal muscle and lung of mice. Biochim Biophys Acta 2001;1520:163-168.